Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata

El-Ashmawy, Amal Ahmad; El-Maadawy, Iman Hamed; El-Maghraby, Gamal Mohamed

doi:10.1080/09546634.2017.1330527

Cited by 23 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Hair regrowth ≥ 50% : Three RCTs with patchy AA (3 parallel) assessed this comparison, one study with 20 children and adults; one study with 80 adults; and one study with 40 children and adults. Significant difference between 5% minoxidil vs. placebo (60% vs. 6% respectively): RR 8.37, 95% CI 3.16–22.14; participants = 151; studies = 3; I ² = 6%; short‐term follow‐up; moderate quality of evidence (Fig.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Minoxidil for patchy alopecia areata: systematic review and meta‐analysis

Freire

Riera

Martimbianco

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Alopecia areata (AA) is a complex immune and polygenic inflammatory disease that causes hair loss on some or all areas of the body; extent, severity and progression vary widely among individuals. Alopecia areata, considered one of the most frequently occurring immune diseases, affects 0.2% of the world population at any given time. Uncertainty prevails about the most appropriate intervention for AA. The aim is to evaluate the effectiveness and safety of over 80 interventions for AA, including minoxidil – one of the most promising interventions for patchy AA in children and adults of both sexes. Material and Methods An extensive search was conducted of international medical literature involving randomized clinical trials (RCTs) of AA interventions. RCTs were evaluated qualitatively and quantitatively according to the previously published protocol and for seven specific outcomes. Results The meta‐analysis involving 5% minoxidil vs. placebo presented a significant difference in favor of 5% minoxidil with the moderate quality of evidence in children and adults with patchy AA (RR 8.37 [3.16–22.14], 95% CI). No severe adverse event was reported. Conclusions Treatment of patchy AA with 5% minoxidil proved effective, and clinically and statistically safe in studies with limited sample size; quality of evidence was moderate. Further studies with sound methodological quality, more participants and outcome observations lasting longer than 6 months are needed to address remaining uncertainties.

show abstract

Section: Resultsmentioning

confidence: 99%

“…5% minoxidil -Primary outcomes [17][18][19] Hair regrowth ≥ 50%: Three RCTs with patchy AA (3 parallel) assessed this comparison, one study 17 with 20 children Figure 4 Forest plot with 5% minoxidil vs. placebo. Significant hair growth ≥50%.…”

Section: Resultsmentioning

confidence: 99%

Minoxidil for patchy alopecia areata: systematic review and meta‐analysis

Freire

Riera

Martimbianco

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Other associated conditions with alopecia areata include atopic dermatitis, celiac disease, pernicious anemia, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, and vitiligo [3,4]. Multiple therapies have been identified as effective treatments for beard alopecia areata ( Table 1) [3][4][5][6][7][8][9][10][11][12][13][14]. Treatment with corticosteroids (either intralesional or topical) is usually the first line of therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Immunosuppressants [5,7], CR Corticosteroids (intralesional injections, topical) [5,7], CR Immunotherapy [6] Anthralin and diphenylcyclopropenone [6] Janus kinase (JAK) inhibitors [3,8,9] Ruxolitinib [8] Tofacitinib [3,9] Laser [10][11][12] 308-nm excimer laser [10] 908-nm diode laser [11] 1,550-nm fractional laser [12] Minoxidil [7] Photodynamic therapy [13] Platelet-rich plasma (PRP) [14] Prostaglandin F2-alpha analogues [7] Latanoprost [7] Treatment of concurrent Helicobacter pylori infection [4] Our patient decided to treat his beard alopecia areata with topical 0.1% triamcinolone acetonide cream. This led to a complete regrowth of his beard hair within six months.…”

Section: Treatment Referencesmentioning

confidence: 99%

See 1 more Smart Citation

Incipient Diabetes Mellitus and Nascent Thyroid Disease Presenting as Beard Alopecia Areata: Case Report and Treatment Review of Alopecia Areata of the Beard

Forouzan

Cohen²

2020

Cureus

View full text Add to dashboard Cite

Alopecia areata is a non-scarring hair loss that commonly presents on the scalp. In men, when this condition results in facial hair loss on the cheek, jaw, and neck, it is referred to as beard alopecia areata. Beard alopecia areata can be associated with autoimmune conditions, such as diabetes mellitus, thyroid disorders, and vitiligo. A 28-year-old man presented with a fivemonth history of facial hair loss; his condition was diagnosed as beard alopecia areata after clinical examination. Treatment with twice daily topical 0.1% triamcinolone acetonide cream led to complete regrowth of his beard hair after six months. There are several potential agents and modalities for the treatment of individuals with beard alopecia areata. Treatment options include corticosteroid therapy (intralesional or topical), immunotherapy, Janus kinase (JAK) inhibitors, lasers, photodynamic therapy, platelet-rich plasma therapy, and treatment of an underlying Helicobacter pylori infection. Laboratory evaluation, prompted by our patient's diagnosis of beard alopecia areata, suggested incipient diabetes mellitus and nascent thyroid disease; specifically, he had elevated fasting blood glucose and elevated thyroid-stimulating hormone levels. Therefore, in patients with beard alopecia areata, laboratory evaluation for concomitant or incipient autoimmune diseases should be considered.

show abstract